Table 1 Selected characteristics and outcomes of the 300 C. difficile assays performed in IBD patients. *: only assessed for screen positive cases

Age, years, median (IQR)

49 (34–62)

221

Male sex, n (%)

143 (47.7)

300

White race, n (%)

248 (82.7)

300

Inpatient location, n (%)

177 (59.2)

299

Screen positive/toxin positive, n (%)

25 (8.3)

300

Screen positive, toxin negative, n (%)

136 (45.3)

Negative screen, n (%)

139 (46.3)

Height, m, median (IQR)

1.7 (1.6–1.8)

142

Weight, kg, median (IQR)

75 (64.2–88.8)

172

BMI, kg/m², median (IQR)

25.8 (22.2–30.4)

141

IBD duration, years, median (IQR)

9.8 (4.5–18.3)

275

Crohns disease, n (%)

160 (53.3)

300

Ulcerative colitis, n (%)

130 (43.3)

IBD-unclassified, n (%)

3 (1)

Pouch, n (%)

7 (2.3)

History of prior CDI, n (%)

87 (29.1)

299

History of prior CDI in the past 8 weeks, n (%)

8 (4.6)

174

Active smoking, n (%)

29 (16.6)

175

IBD therapies

 Steroids, n (%)

106 (35.3)

300

 IMM, n (%)

63 (21)

300

 Anti-TNF, n (%)

81 (27)

300

 Vedolizumab, n (%)

33 (11)

300

 Ustekinumab, n (%)

16 (5.3)

300

 Tofacitinib, n (%)

9 (3)

300

 Proton pump inhibitor, n (%)

113 (37.7)

300

 Antibiotic use in the past 4 weeks, n (%)

18 (10.3)

175

CDI Therapy*

 No treatment, n (%)

23 (14.7)

156

 Metronidazole, n (%)

9 (5.8)

156

 Vancomycin, n (%)

107 (68.6)

156

 Metronidazole and vancomycin, n (%)

11 (7.1)

156

 Fidaxomicin, n (%)

3 (1.9)

156

 Fecal microbiota transplant, n (%)

3 (1.9)

156

Outcomes

 Death within 30 days, n (%)

4 (1.3)

300

 Total colectomy or diverting ostomy, n (%)

11 (3.7)

300

 ICU admission, n (%)

4 (1.3)

300

 Primary combined outcome, n (%)

17 (5.7)

300

 Any intraabdominal surgery, n (%)

23 (7.7)

300

 Escalation in IBD therapy, n (%)

75 (25)

300

Laboratory values

 WBC, 10³/µL, median (IQR)

10.2 (7.4–14.7)

244

 Hgb, g/dL, median (IQR)

10.6 (8.9–12.6)

245

 Albumin, g/dL, median (IQR)

3.5 (2.9–4.1)

213

 C-reactive protein, mg/L, median (IQR)

7.8 (3.1–37)

163